Quarterly ResultJul 23, 2026, 01:01 AM
argenx Q2 Sales Hit $1.5B, Up 60% YoY; Expanded VYVGART Label
AI Summary
argenx SE reported strong second-quarter 2026 results with global product net sales of $1.5 billion, marking a 60% year-over-year and 17% quarter-over-quarter growth. The company successfully launched an expanded label for VYVGART and VYVGART Hytrulo to include all gMG serotypes, broadening patient reach. Key registrational study readouts for autoimmune myositis and multifocal motor neuropathy (MMN) are on track for Q3 and Q4 2026, respectively, supporting pipeline expansion. The company also reported a significant increase in operating profit and profit for the period.
Key Highlights
- Q2 2026 global product net sales reached $1.5 billion.
- Product net sales grew 60% year-over-year and 17% quarter-over-quarter.
- Expanded VYVGART and VYVGART Hytrulo label to include all gMG serotypes.
- Registrational autoimmune myositis study readout on track for Q3 2026.
- Registrational MMN study readout for empasiprubart on track for Q4 2026.
- Q2 2026 operating profit was $494 million, up from $201 million in Q2 2025.
- Q2 2026 profit for the period was $472 million, up from $245 million in Q2 2025.
- Cash, cash equivalents, and current financial assets totaled $5.2 billion as of June 30, 2026.
Price Impact
More from ARGX